Cardio-oncology & otherCohort study
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors
- Retrospective cohort study
- propensity-score matched
- administrative claims databases
Authors' conclusion
Premenopausal patients with breast cancer treated with aromatase inhibitors and ovarian suppression may be at elevated risk for CVD
Study context
- Population
- Enrollees younger than 55 years with incident breast cancer, MarketScan claims databases, 2013–2020matched cohort
- Exposure
- Aromatase inhibitor plus ovarian suppression vs tamoxifen
- Outcome
- Incident cardiovascular disease (CVD) (AF, MI, stroke, HF hospitalization, angina or coronary revascularization)
- Follow-up
- Median 1.55 years
Main finding
As reported in the abstract
Hazard ratio
2.20
95% CI 1.57–3.09
Events by group
Aromatase inhibitors plus ovarian suppression
2.3 per 100 person-years
51 events
Tamoxifen
1.0 per 100 person-years
102 events
Aromatase inhibitors plus ovarian suppression vs Tamoxifen
HR 2.20 (95% CI 1.57–3.09)
- Incidence rate difference
- 0.012 (95% CI 0.006-0.019)
Observational data: associations, not effects.
Original publication
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors. JACC CardioOncol. Published 8 October 2024. doi:10.1016/j.jaccao.2024.08.006
Summarised from the published abstract; every number is checked against it